Cancer Genetics Inc. (NASDAQ:CGIX) shares traded down 3.4% on Friday . The company traded as low as $1.97 and last traded at $2.00, with a volume of 74,460 shares trading hands. The stock had previously closed at $2.07.

A number of research analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Cancer Genetics from a “buy” rating to a “hold” rating in a research report on Thursday, April 21st. Janney Montgomery Scott reaffirmed a “neutral” rating on shares of Cancer Genetics in a report on Friday, March 11th. Finally, Aegis raised their price objective on shares of Cancer Genetics from $8.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, March 15th.

The firm’s market capitalization is $27.30 million. The company has a 50-day moving average of $2.07 and a 200-day moving average of $2.44.

Cancer Genetics (NASDAQ:CGIX) last issued its earnings results on Tuesday, May 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.04. The firm earned $6.10 million during the quarter, compared to analysts’ expectations of $6.95 million. The firm’s quarterly revenue was up 38.6% on a year-over-year basis. During the same period last year, the firm posted ($0.44) earnings per share. On average, analysts predict that Cancer Genetics Inc. will post ($1.26) earnings per share for the current year.

Cancer Genetics, Inc is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.